Item Type | Name |
Concept
|
Patient Care
|
Concept
|
Patient Education as Topic
|
Concept
|
Patient Advocacy
|
Concept
|
Patient Acceptance of Health Care
|
Concept
|
Patients
|
Concept
|
Analgesia, Patient-Controlled
|
Concept
|
Patient-Centered Care
|
Concept
|
Patient Protection and Affordable Care Act
|
Concept
|
Patient Participation
|
Concept
|
Patient Satisfaction
|
Concept
|
Patient Selection
|
Concept
|
Patient Compliance
|
Concept
|
Physician-Patient Relations
|
Concept
|
Patient Safety
|
Academic Article
|
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
|
Academic Article
|
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
|
Academic Article
|
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
|
Academic Article
|
Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.
|
Academic Article
|
New phase I trial methodology.
|
Academic Article
|
Learning from our patients: one participant's impact on clinical trial research and informed consent.
|
Academic Article
|
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
|
Academic Article
|
Study of cohort-specific consent and patient control in phase I cancer trials.
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
|
Academic Article
|
Evaluation of neuropathy in patients on suramin treatment.
|
Academic Article
|
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
|
Academic Article
|
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
|
Academic Article
|
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
|
Academic Article
|
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
|
Academic Article
|
Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients.
|
Academic Article
|
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
|
Academic Article
|
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
|
Academic Article
|
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
|
Academic Article
|
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients.
|
Academic Article
|
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
|
Academic Article
|
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
|
Academic Article
|
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
|
Academic Article
|
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
|
Academic Article
|
Elimination pathways of [14C]losoxantrone in four cancer patients.
|
Academic Article
|
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
|
Academic Article
|
Troxacitabine in patients with refractory leukemia.
|
Academic Article
|
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
|
Academic Article
|
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
|
Academic Article
|
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
Academic Article
|
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
|
Academic Article
|
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.
|
Academic Article
|
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
Academic Article
|
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
|
Academic Article
|
Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs.
|
Academic Article
|
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
|
Academic Article
|
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
|
Academic Article
|
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.
|
Academic Article
|
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
|
Academic Article
|
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
|
Academic Article
|
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
|
Academic Article
|
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
|
Academic Article
|
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
|
Academic Article
|
Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
|
Academic Article
|
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
|
Academic Article
|
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
|
Academic Article
|
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
|
Academic Article
|
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
|
Academic Article
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
Academic Article
|
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
|
Academic Article
|
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials.
|
Academic Article
|
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
|
Academic Article
|
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
|
Academic Article
|
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
|
Academic Article
|
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.
|
Academic Article
|
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
|
Academic Article
|
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
|
Academic Article
|
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
|
Academic Article
|
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
|
Academic Article
|
Dose reduction of etoposide in jaundiced patients.
|
Academic Article
|
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
|
Academic Article
|
Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.
|
Academic Article
|
A phase I study of continuous infusion cilengitide in patients with solid tumors.
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
Academic Article
|
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
|
Academic Article
|
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
|
Academic Article
|
Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.
|
Academic Article
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
Academic Article
|
Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia.
|
Academic Article
|
Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986.
|
Academic Article
|
Prognostic factors for survival in patients treated in phase I clinical trials.
|
Academic Article
|
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
|
Academic Article
|
A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.
|
Academic Article
|
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
|
Academic Article
|
Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia.
|
Academic Article
|
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.
|
Academic Article
|
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
|
Academic Article
|
Randomized phase II trials: a long-term investment with promising returns.
|
Academic Article
|
Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
|
Academic Article
|
Pharmacogenomics and patient care: one size does not fit all.
|
Academic Article
|
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
|
Academic Article
|
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
|
Academic Article
|
Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b.
|
Academic Article
|
A phase I study of intermittent infusion cladribine in patients with solid tumors.
|
Academic Article
|
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
|
Academic Article
|
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
|
Academic Article
|
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
|
Academic Article
|
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
|
Academic Article
|
Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986.
|
Academic Article
|
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
|
Academic Article
|
Perceptions of cancer patients and their physicians involved in phase I trials.
|
Academic Article
|
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials.
|
Academic Article
|
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
|
Academic Article
|
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
|
Academic Article
|
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
|
Academic Article
|
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.
|
Academic Article
|
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
|
Academic Article
|
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
|
Academic Article
|
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
|
Academic Article
|
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
|
Academic Article
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
Academic Article
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
Academic Article
|
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
|
Academic Article
|
Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
|
Academic Article
|
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
|
Academic Article
|
Phase-I trial of Thiotepa, granulocyte-macrophage colony-stimulating factor and prednisone or pentoxifylline in patients with refractory solid tumors.
|
Academic Article
|
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
|
Academic Article
|
Playing Russian roulette with tyrosine kinase inhibitors.
|
Academic Article
|
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
|
Academic Article
|
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.
|
Academic Article
|
Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer.
|
Academic Article
|
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
|
Academic Article
|
Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design.
|
Academic Article
|
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
|
Academic Article
|
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
|
Academic Article
|
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
|
Academic Article
|
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
|
Academic Article
|
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).
|
Academic Article
|
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
|
Academic Article
|
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance).
|
Academic Article
|
Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project".
|
Academic Article
|
The development of a financial toxicity patient-reported outcome in cancer: The COST measure.
|
Academic Article
|
Forecasting unanticipated consequences of "The Sunshine Act": mostly cloudy.
|
Academic Article
|
User beware: we need more science and less art when measuring financial toxicity in oncology.
|
Academic Article
|
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
|
Academic Article
|
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.
|
Academic Article
|
Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).
|
Academic Article
|
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
|
Academic Article
|
Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs.
|
Academic Article
|
Interferon Alfa-2b Antibodies and Clinical Resistance in a Patient with Hairy Cell Leukemia.
|
Academic Article
|
Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2B.
|
Academic Article
|
Low Dose Interferon Alfa-2B for the Induction of Remission of Hairy Cell Leukemia: A Multi-institutional Study of 49 Patients.
|
Academic Article
|
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).
|
Academic Article
|
Drug-Drug Interactions With Oral Antineoplastic Agents.
|
Academic Article
|
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program.
|
Academic Article
|
A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC).
|
Academic Article
|
A study of informed consent (IC), age, and cognitive performance (CP) among advanced cancer patients (acp) in phase I trials.
|
Academic Article
|
Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
|
Academic Article
|
Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms.
|
Academic Article
|
A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies.
|
Academic Article
|
Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation.
|
Academic Article
|
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
|
Academic Article
|
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
|
Academic Article
|
Genetic variation determines VEGF-A plasma levels in cancer patients.
|
Academic Article
|
Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?
|
Academic Article
|
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
|
Academic Article
|
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
|
Academic Article
|
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
|
Academic Article
|
Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.
|
Academic Article
|
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
|
Academic Article
|
Assessment of Patient Knowledge and Perceptions of Pharmacogenomics Before and After Using a Mock Results Patient Web Portal.
|
Academic Article
|
Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation.
|
Academic Article
|
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
|
Academic Article
|
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
|
Academic Article
|
Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients.
|
Academic Article
|
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Letter.
|
Academic Article
|
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
|
Academic Article
|
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
|
Academic Article
|
Patient insights on features of an effective pharmacogenomics patient portal.
|
Academic Article
|
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance).
|
Academic Article
|
Negative innovation: when patents are bad for patients.
|
Academic Article
|
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
|
Academic Article
|
Creation of a pharmacogenomics patient portal complementary to an existing institutional provider-facing clinical decision support system.
|
Academic Article
|
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
|
Academic Article
|
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
|
Academic Article
|
Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics.
|
Academic Article
|
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
|
Academic Article
|
Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients.
|
Academic Article
|
Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
|
Academic Article
|
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings.
|
Academic Article
|
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
|
Academic Article
|
Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware.
|
Concept
|
Patient Reported Outcome Measures
|
Concept
|
Patient Portals
|
Concept
|
Patient Outcome Assessment
|
Concept
|
Patient Harm
|
Academic Article
|
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.
|
Academic Article
|
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-ß2 levels in metastatic colorectal cancer patients (Alliance).
|
Academic Article
|
Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy.
|
Academic Article
|
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).
|